GPhA supports actions to release more affordable generic drugs

ARLINGTON, Va. A statement by a think-tank researcher Wednesday that critiqued biogeneric market exclusivity drew praise from an organization representing the generic drug industry.

Alex Brill, a research fellow at the American Enterprise Institute and former chief economist for the House Ways and Means Committee, released a paper Wednesday critiquing the Biotechnology Industry Organization’s argument for long-term exclusivity for biologic drugs.

“As the economy continues to struggle and countless Americans are cutting back on health care, the Obama Administration and the new Congress must focus on how to increase access to quality care while reducing costs,” Generic Pharmaceutical Association president and chief executive officer Kathleen Jaeger said in a statement. “Now, more than ever, it is critical that as Congress considers biogenerics legislation, it provides a solution that brings safe and affordable biogenerics to patients sooner rather than later.”